Last reviewed · How we verify

NCT06941961

iTBS for Acute Ischemic Stroke After Thrombectomy

Recruiting now NA Last updated 30 April 2025
What this trial tests

NA trial testing intermittent theta burst stimulation in Ischemic Stroke in 178 participants. Currently enrolling.

Timeline
25 April 2025
Primary endpoint
1 July 2026
1 August 2026

Quick facts

Lead sponsorYi Yang
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment178
Start date25 April 2025
Primary completion1 July 2026
Estimated completion1 August 2026
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Yi Yang — full company profile →

Who can join

Adults 18 to 85, any sex, with Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this randomized, single-blind, parallel-controlled clinical trial is to evaluate the efficacy and safety of intermittent theta burst stimulation (iTBS) as an adjunctive therapy for acute anterior circulation ischemic stroke patients who have undergone successful mechanical thrombectomy (MT). The study population includes adults aged 18-85 with NIHSS scores 5-25 post-MT and eTICI≥2b reperfusion.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of intermittent theta burst stimulation

Trials testing the same drug.

Other recruiting trials for Ischemic Stroke

Currently open trials in the same condition.

Other Yi Yang trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06941961.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing